Clinical Trials · NCT02759107
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 142
- Start date
- May 2016
- Locations
- 2 sites, United States, Singapore
- Primary endpoint
- Number of Participants With One or More Serious Adverse Event(s) (SAEs)